We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | 0.14% | 35.45 | 35.20 | 35.60 | 35.65 | 35.20 | 35.45 | 246,675 | 16:35:25 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.14 | 105.85M |
From Apr 2019 to Apr 2024
TIDMFUM
RNS Number : 0387J
Futura Medical PLC
30 November 2018
Block Listing Update
30 November 2018
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
The table below provides further detail. The figures include the block admission of 1,765,000 Ordinary Shares earlier today, as announced on 26 November 2018.
Hot Features
Premium
Name of company: Futura Medical plc
Name of scheme(s): Unapproved Share Option Scheme ("USOS")
Unapproved Share Incentive Scheme ("USIS")
EMI Share Option Scheme ("EMI")
Period of return: From: 31 May 2018
To: 30 November 2018
USOS: 2,343,965
USIS: -
EMI: 2,843,535
Number and class of securities
not issued under the scheme(s)
at beginning of period Total: 5,187,500
------------------------------ ------------------------------
Number and class of securities USOS: -
admitted to the scheme(s) in the
period
USIS: 425,000
EMI: 1,340,000
Total: 1,765,000
------------------------------ ------------------------------
Number of securities issued USOS: -
under the scheme(s) during the
period
USIS: -
EMI: -
Total: -
------------------------------ ------------------------------
Number of securities lapsed
under the scheme(s) during the
period USOS: 350,090
USIS: -
EMI: 377,410
Total: 727,500
------------------------------ ------------------------------
Balance of securities under the
scheme(s) not yet issued at the
end of the period USOS: 1,993,875
USIS: 425,000
EMI: 3,806,125
Total: 6,225,000
------------------------------ ------------------------------
Number and class of securities USOS: 814,424 25 May 2011,
originally admitted and the date 1,202,280 8 October
of admission 2013,
1,466,208 25 May 2017,
400,000 30 May 2018,
USOS Total: 3,882,912
------------------------------ ------------------------------
USIS: 425,000 30 November
2018
USIS Total: 425,000
------------------------------ ------------------------------
EMI: 1,520,576 25 May 2011,
1,467,720 8 October
2013,
1,893,792 25 May 2017,
790,000 30 May 2018,
1,340,000 30 November
2018
EMI Total: 7,012,088
------------------------------ ------------------------------
Total: 11,320,000
------------------------------ ------------------------------
Name of contact: Angela Hildreth, Finance Director/Chief Operating Officer
Telephone number of contact: +44 (0) 1483 685 670
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)
Tom Salvesen/ Mia Gardner (Corporate Broking)
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BLRWGGQCGUPRURU
(END) Dow Jones Newswires
November 30, 2018 03:54 ET (08:54 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
